



**ALTERNATE HEALTH CORP. (CSE:AHG) (OTC: AHGIF)
ANNOUNCED BOARD RESTRUCTURING AND APPOINTING A NEW
CEO AND CHAIRMAN.**

PLANO, Texas, April 5, 2017 – [Alternate Health Corp.](#) (CSE:AHG) (OTC:AHGIF) today announced that it has named Dr. Jamison Feramisco as CEO (current AHC Director) and Dr. Michael Murphy as Chairman of the Board of Directors. These appointments represent significance in bringing additional clinical corporate expertise in the oversight of Alternate Health’s emerging medical operations.

Dr. Feramisco is an M.D.,Ph.D., and is a graduate of the University of Texas at Southwestern Medical School. He is trained in both Internal Medicine and Dermatology and conducted his thesis research in the labs of Nobel Laurates Drs. Michael Brown and Joseph Goldstein MD, earning a Ph.D. degree in Molecular Genetics and Biochemistry. Dr. Feramisco brings Alternate Health a high level of experience and success in transforming corporate growth to profitability, strategic mergers and acquisitions, regulatory oversight and dynamic healthcare innovation across medical technology, digital health, big data analytics, and clinical services.

Dr. Michael Murphy currently manages the Alternate Health Clinical Laboratories and is the majority interest shareholder in Clover Trail LLC, a foundational partner of Alternate Health. Dr. Murphy is a M.D. specializing in Anesthesiology and Interventional Pain Management with a focus on alleviating chronic pain. He holds a very successful track record in acquiring and managing several medical service practices, clinics and Ambulatory Surgery Centers. He has also served on the Boards of various financial institutions. His wealth of experience and knowledge in laboratory operations, management, and regulatory compliance will serve a key function in supporting Alternate Health’s business.

Alternate Health would also like to announce the resignation of Bryan Korba as Chairman, CEO and Director. Mr. Korba was hired to transition Alternate Health into a public listing, and to recruit and engage a suitable management team to grow the company.

“We are thrilled with the substantive work that Mr. Korba has done for Alternate Health thus far,” said Dr. Jamison Feramisco, CEO. “He has provided a strong foundation by which myself and the Board can further to grow and expand the services of the company. We have requested that Bryan continue his contributions and stay with us as President of Alternate Health.”

About Alternate Health Corp.

[Alternate Health Corp](#) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact:

For further information, please contact Jim Griffiths at 416-607-5757

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.